An observational study assessing the development of anti-drug antibodies against TNFi longitudinally during 2-years period in patients with Axial Spondyloarthritis and factors associated with it
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
- Indications Axial spondyloarthritis
- Focus Adverse reactions; Therapeutic Use
- 09 Nov 2021 Results assessing the development of ADA against TNFi longitudinally during 2-years period in axSpA patients and factors associated with it presented at the ACR Convergence 2021
- 20 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism